Advanced search
Publication Cover
Current Medical Research and Opinion Volume 37, 2021 - Issue 3
Submit an article Journal homepage
1,933
Views
1
CrossRef citations to date
0
Altmetric
Nephrology

Consequences of insurance denials among U.S. patients prescribed repository corticotropin injection (Acthar Gel) for nephrotic syndrome

J. Bradford Ricea Analysis Group Inc., Boston, MA, USACorrespondence[email protected]
,
Mary P. Panacciob Mallinckrodt Pharmaceuticals, Bedminster Township, NJ, USA
,
Alan Whitea Analysis Group Inc., Boston, MA, USA
,
Mark Simesa Analysis Group Inc., Boston, MA, USA
,
Emma Billmyera Analysis Group Inc., Boston, MA, USA
,
Nathaniel Downesa Analysis Group Inc., Boston, MA, USA
,
John Niewoehnerb Mallinckrodt Pharmaceuticals, Bedminster Township, NJ, USA
&
George J. Wanb Mallinckrodt Pharmaceuticals, Bedminster Township, NJ, USA
 show all
Pages 431-441 | Received 14 Oct 2020, Accepted 04 Jan 2021, Published online: 02 Feb 2021

References

  • Hull RP, Goldsmith DJ. Nephrotic syndrome in adults. BMJ. 2008;336(7654):1185–1189.
  • Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med. 1998;338(17):1202–1211.
  • National Institute of Diabetes and Digestive and Kidney Diseases: National Institutes of Health. Nephrotic syndrome in adults; 2014 [cited 2020 Aug 18]. Available from: https://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults.
  • Bomback AS, Tumlin JA, Baranski J, et al. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des Dev Ther. 2011;5:147–153.
  • Madan A, Mijovic-Das S, Stankovic A, et al. Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series. BMC Nephrol. 2016;17(1):37.
  • Bomback AS, Canetta PA, Beck LH, Jr, et al. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Am J Nephrol. 2012;36(1):58–67.
  • Pilon D, Sheehan JJ, Szukis H, et al. Medicaid spending burden among beneficiaries with treatment-resistant depression. J Comp Eff Res. 2019;8(6):381–392.
  • Tumlin JA, Galphin CM, Rovin BH. Steroid resistant nephrotic syndrome: a prospective, open label study of the safety and efficacy of combination tacrolimus and ACTHar gel therapy [ASN abstract FR-PO434]. J Am Soc Nephrol. 2015;26(Suppl):455A.
  • Tumlin JA, Rovin BH, Paxton WG, et al. A prospective, open label study of the safety and treatment efficacy of ACTHar gel for fibrillary glomerulonepritis [ASN abstract SA-PO659]. J Am Soc Nephrol. 2016;27(Suppl):781A.
  • Tumlin J, Galphin C, Santos R, et al. Safety and efficacy of combination ACTHar gel and tacrolimus in treatment-resistant focal segmental glomerulosclerosis and membranous glomerulopathy. Kidney Int Rep. 2017;2(5):924–932.
  • Madan A. Repository corticotropin injection in a patient presenting with focal segmental glomerulosclerosis, rheumatoid arthritis, and optic neuritis: a case report. Int J Gen Med. 2015;8:119–124.
  • Madan A, Mijovic-Das S, Stankovic A, et al. Treatment response to Acthar Gel in patients with idiopathic focal segmental glomerulosclerosis and idiopathic membranous nephropathy: a retrospective case series [ASN abstract TH-PO437]. J Am Soc Nephrol. 2014;25(Suppl):206A.
  • Reuben S, Maroz N. Treatment of Fibrillary Glomerulonephritis with Use of Repository Corticotropin Injection (Acthar) [ASN abstract TH-PO018]. J Am Soc Nephrol. 2016;27(Suppl):99A.
  • Bonilla NA, Parada XF, Henriquez MA. A case series on the treatment of nephrotic syndrome with adrenocorticotropin hormone (ACTH) gel in an office setting [ASN abstract PUB219]. J Am Soc Nephrol. 2015;26(Suppl):937A.
  • Filippone EJ, Dopson SJ, Rivers DM, et al. Adrenocorticotropic hormone analog use for podocytopathies. IMCRJ. 2016;9:125–133.
  • Marayati F, Long-Term HP. Acthar gel treatment of relapsing idiopathic membranous glomerulopathy: a case study [ASN abstract PUB206]. J Am Soc Nephrol. 2015;26(Suppl):934A.
  • McMahon BA, Berliner AR. Treatment of severe resistant idiopathic membranous glomerulopathy with adrenocorticotropic hormone gel: a case report [ASN abstract SA-PO032]. J Am Soc Nephrol. 2015;26(Suppl):631A.
  • Hladunewich MA, Cattran D, Beck LH, et al. A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar Gel) in nephrotic syndrome due to idiopathic membranous nephropathy. Nephrol Dial Transplant. 2014;29(8):1570–1577.
  • Lieberman KV, Pavlova-Wolf A. Adrenocorticotropic hormone therapy for the treatment of idiopathic nephrotic syndrome in children and young adults: a systematic review of early clinical studies with contemporary relevance. J Nephrol. 2017;30(1):35–44.
  • Hogan J, Bomback AS, Mehta K, et al. Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. Clin J Am Soc Nephrol. 2013;8(12):2072–2081.
  • Park Y, Raza S, George A, et al. The effect of formulary restrictions on patient and payer outcomes: a systematic literature review. J Manag Care Spec Pharm. 2017;23(8):893–901.
  • Rice JB, Panaccio MP, White A, et al. Consequences of insurance denials among U.S. patients prescribed repository corticotropin injection for acute exacerbations of multiple sclerosis. Neurol Ther. 2020. DOI:10.1007/s40120-020-00219-y
  • Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424.
  • Nazareth TA, Kariburyo F, Kirkemo A, et al. Patients with idiopathic membranous nephropathy: a real-world clinical and economic analysis of U.S. claims data. J Manag Care Spec Pharm. 2019;25(9):1011–1020.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.